.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
AstraZeneca
Moodys
Medtronic
Colorcon
Farmers Insurance
Baxter
QuintilesIMS
Accenture
Teva

Generated: December 12, 2017

DrugPatentWatch Database Preview

Galderma Labs Lp Company Profile

« Back to Dashboard

What is the competitive landscape for GALDERMA LABS LP, and when can generic versions of GALDERMA LABS LP drugs launch?

GALDERMA LABS LP has twenty-three approved drugs.

There are sixty US patents protecting GALDERMA LABS LP drugs and there have been two Paragraph IV challenges on GALDERMA LABS LP drugs in the past three years.

There are three hundred and seventy-six patent family members on GALDERMA LABS LP drugs in thirty-four countries and ninety-two supplementary protection certificates in fifteen countries.

Summary for Galderma Labs Lp

International Patents:376
US Patents:60
Tradenames:15
Ingredients:13
NDAs:23
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Galderma Labs LpMETROGELmetronidazoleGEL;TOPICAL021789-001Jun 30, 2005ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galderma Labs LpSOOLANTRAivermectinCREAM;TOPICAL206255-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galderma Labs LpEPIDUOadapalene; benzoyl peroxideGEL;TOPICAL022320-001Dec 8, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Galderma Labs LpMIRVASObrimonidine tartrateGEL;TOPICAL204708-001Aug 23, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneGEL;TOPICAL021753-001Jun 19, 2007ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Galderma Labs LpEPIDUOadapalene; benzoyl peroxideGEL;TOPICAL022320-001Dec 8, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Galderma Labs LpSOOLANTRAivermectinCREAM;TOPICAL206255-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Galderma Labs LpEPIDUOadapalene; benzoyl peroxideGEL;TOPICAL022320-001Dec 8, 2008ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Galderma Labs Lp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs LpDIFFERINadapaleneSOLUTION;TOPICAL020338-001May 31, 1996► Subscribe► Subscribe
Galderma Labs LpMETROGELmetronidazoleGEL;TOPICAL019737-001Nov 22, 1988► Subscribe► Subscribe
Galderma Labs LpORACEAdoxycyclineCAPSULE;ORAL050805-001May 26, 2006► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneCREAM;TOPICAL020748-001May 26, 2000► Subscribe► Subscribe
Galderma Labs LpEPIDUOadapalene; benzoyl peroxideGEL;TOPICAL022320-001Dec 8, 2008► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneGEL;TOPICAL021753-001Jun 19, 2007► Subscribe► Subscribe
Galderma Labs LpCLOBEXclobetasol propionateLOTION;TOPICAL021535-001Jul 24, 2003► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneSOLUTION;TOPICAL020338-001May 31, 1996► Subscribe► Subscribe
Galderma Labs LpDIFFERINadapaleneGEL;TOPICAL021753-001Jun 19, 2007► Subscribe► Subscribe
Galderma Labs LpMETVIXIAmethyl aminolevulinate hydrochlorideCREAM;TOPICAL021415-001Jul 27, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GALDERMA LABS LP drugs

Drugname Dosage Strength Tradename Submissiondate
ivermectinCream1%SOOLANTRA12/30/2016
brimonidineTopical Gel0.33%MIRVASO12/15/2014
adapalene and benzoyl peroxideGel0.1%/2.5%EPIDUO12/30/2011
adapaleneTopical Gel0.30%DIFFERIN9/15/2009
doxycyclineDelayed-release Capsules40 mgORACEA12/11/2008
metronidazoleTopical Gel1%METROGEL10/21/2008
clobetasol propionateSpray0.05%CLOBEX9/29/2008
clobetasol propionateTopical Shampoo0.05%CLOBEX1/9/2008
clobetasol propionateLotion0.05%CLOBEX3/27/2006

Non-Orange Book Patents for Galderma Labs Lp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,729,127Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders► Subscribe
8,624,678Output stage of a power amplifier having a switched-bulk biasing and adaptive biasing► Subscribe
9,381,179Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders► Subscribe
9,258,687Method and system for providing tiered access to communication network resources► Subscribe
8,611,848Method and system for providing tiered access to communication network resources► Subscribe
9,814,690Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt► Subscribe
5,886,038 Composition and method for treatment of psoriasis► Subscribe
9,622,994Method for the treatment of acne using pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid► Subscribe
7,838,563Compounds, formulations, and methods for ameliorating telangiectasias► Subscribe
8,653,140Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Galderma Labs Lp Drugs

Country Document Number Estimated Expiration
SloveniaEP2388007► Subscribe
CroatiaP20150940► Subscribe
World Intellectual Property Organization (WIPO)2008092911► Subscribe
Hong Kong1223040► Subscribe
Hong Kong1073996► Subscribe
Cyprus1108868► Subscribe
Japan2014040481► Subscribe
JapanH10101549► Subscribe
Japan5722598► Subscribe
Austria330615► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Galderma Labs Lp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C/GB99/001United Kingdom► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGEN SULPHATE, THE DEXTROROTATORY ISOMER OF ALPHA-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRID-5-YL)(2-CHLOROPHENYL) METHYL ACETATE AS THE HYDROGEN SULPHATE SALT; REGISTERED: UK EU/1/98/069/001 19980715; UK EU/1/98/069/002 19980715; UK EU/1/98/069/003 19980715
488Luxembourg► SubscribePRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140130
01C/040Belgium► SubscribePRODUCT NAME: MONOHYDRATE DU CHLORHYDRATE DE N,N-DIMETHYL-1-4-CHLOROPHENYL)CYCLOBUTYL-3-METHYLBUTYLAMINE ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT; NAT. REGISTRTION NO/DATE: 479 IS 52 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113
C0056France► SubscribePRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
2014 00055Denmark► SubscribePRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630
C0024France► SubscribePRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
C/GB04/034United Kingdom► SubscribePRODUCT NAME: PREGABALIN (S-(+)-4-AMINO-3(2-METHYLPROPYL)BUTANOIC ACID) OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACTIVE SALT.; REGISTERED: UK EU/1/04/279/001 20040706; UK EU/1/04/279/002 20040706; UK EU/1/04/279/003 20040706; UK EU/1/04/279/004 20040706; UK EU/1/04/279/005 20040706; UK EU/1/04/279/006 20040706; UK EU/1/04/279/025 20040706; UK EU/1/04/279/019 20040706; UK EU/1/04/279/020 20040706; UK EU/1/04/279/021 20040706; UK EU/1/04/279/022 20040706; UK EU/1/04/279/023 20040706; UK EU/1/04/279/024 20040706; UK EU/1/04/279/013 20040706; UK EU/1/04/279/014 20040706; UK EU/1/04/279/015 20040706; UK EU/1/04/279/016 20040706; UK EU/1/04/279/017 20040706; UK EU/1/04/279/018 20040706; UK EU/
0812Netherlands► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124
2010 00036Denmark► SubscribePRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
QuintilesIMS
Mallinckrodt
Chinese Patent Office
Daiichi Sankyo
Argus Health
Federal Trade Commission
Cerilliant
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot